logo
Share SHARE
FONT-SIZE Plus   Neg

Ind-Swift Labs Gets US FDA Nod For 5 APIs For Its Derabassi Facility

Pharma major Ind-Swift Laboratories Ltd. has obtained the US FDA nod for its five Active Pharmaceutical Ingredients or APIs manufactured at its Derabassi manufacturing facility.

The products for which the company has obtained the approval are Naratriptan Hydrochloride (anti-migraine), Ropinirole Hydrochloride (anti-Parkinson's disease), Donepezil Hydrochloride (anti-Alzheimer's disease), Acamprosate Calcium (anti-alcohol dependence) and Clarithromycin (Macrolide antibiotic).

With this approval, the company will be able to sell its products in the US market. The worldwide market for these products is $5 billion.

The company's Derabassi facility is already accredited by key accreditation agencies such as TGA, MHRA, COS, KFDA and PMDA.

Commenting on the development, Vice Chairman and Managing Director N.R. Munjal said, "This multi product approval will give multifold aggression to the sales as we have good presence in US through our US subsidiary and we expect this approval to give additional 50 percent to 60 percent growth in US sales."

At the BSE, Ind-Swift Laboratories closed Tuesday's trading at Rs.98.65, up 3.30 percent from the previous close.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Computer and printer maker Hewlett-Packard Co. said Thursday after the markets closed that its second quarter profit fell 21% from last year, hurt by lower revenue and costs related to the planned separation of the company. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations, but its quarterly revenue fell short of analysts' forecast. Accounting software maker Intuit reported a plunge in third-quarter profit, hurt by impairment charges, even as results topped Wall Street estimates, driven by growth in small business segment amid a strong tax season. Struggling teen-apparel retailer Aeropostale Inc. (ARO), Thursday said its first-quarter loss narrowed from a year ago, driven largely by stronger margins even as revenues continued to plunge dropped. Nevertheless, the company lost almost one-fifth of its market value in after-hours trade, with the...
comments powered by Disqus
Follow RTT